BioPharma licensing and M&A trends

Nature Reviews Drug Discovery

Volumn 4, Issue 4, 2005, Pages 273-274

  Pavlou, Alex K ^a   Belsey, Mark ^a  

^a Datamonitor Healthcare   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMMERCIAL PHENOMENA; DRUG APPROVAL; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; ECONOMIC ASPECT; FINANCIAL MANAGEMENT; HUMAN; LICENCE; NOTE; PATENT; PRESCRIPTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; ARTICLE; ECONOMICS; LEGAL ASPECT; LICENSING;

DRUG INDUSTRY; LICENSURE;

EID: 18244403764     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1697     Document Type: Note

References (3)

1. Pharmaceutical Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2004 [online],
2. Friedman, M. A. Testimony on 1998 budget proposal [online], (1997).
3. US FDA. FDA sees rebound in approval of innovative drugs in 2003; new innovation initiative anticipated to speed approvals in years ahead [online], (2004)